Company Long-Term Loans and Borrowings: Cerevel (CERE)

Brandmark of Cerevel (CERE)

Geopolitical tensions and sanctions are hindering international research and component supplies, which slows down drug certification. This chart of Cerevel Therapeutics (CERE) market valuation on GURU.Markets, where the indicator stands at 0.50, links these risks to the development of treatments for epilepsy and Parkinson's disease. The diversity of testing stages minimizes these threats. High demand for such innovations is confirmed by interest from pharmaceutical behemoths.

Cerevel Therapeutics, Inc. (CERE) Company Long-Term Debts: for the period 07/04/2022 - 08/10/2024

Summary analytical data breakdowns for Cerevel (CERE)

- market price and analyst price targets:
Stock Price cerevel.com|CERE - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Cerevel Therapeutics|CERE - Total Company Value
- book capitalization information:
Net Asset Value per Share Cerevel Therapeutics|CERE - Book Capitalization|Market Cap to Net Assets Ratio cerevel.com|CERE - Company Total Assets
- debt level and financial liquidity data:
Debt to Capital Cerevel Therapeutics|CERE - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Cerevel Corp|CERE - Company Aggregate Debts|Debts to Book Value Cerevel Therapeutics|CERE - Company Long-Term Liabilities|Company Short-Term Debt Cerevel Therapeutics|Immediate Liquidity cerevel.com
- earnings and market multiples details:
CERE - Company Net Income
Summary company analytics:Cerevel Therapeutics
Manufactured product of Cerevel Corp

Developing therapies for neurological diseases requires colossal R&D and clinical trial expenditures. The high cost of innovation directly shapes the liability structure reflected in this indicator. This metric aggregates all debts with a maturity of more than one year. Analyzing the long-term borrowed capital of Cerevel Therapeutics (CERE) allows for an assessment of financial stability in the face of regulatory risks. A stable trajectory of the line confirms solvency but may signal a deficit of investment in breakthrough technologies.

Competitor analysis for Cerevel Therapeutics

Company Long-Term Debts biogen.com BIIB|NBIX - Company Long-Term Debt|Company Long-Term Loans and Borrowings RGC (Regencell Bioscience Ltd)|Axsome Therapeutics Inc (AXSM) - Company Long-Term Debt|Long-Term Debt ACADIA Corp (ACAD)|XENE (Xenon Pharmaceuticals) - Company Long-Term Debts|Company Long-Term Liabilities vikingtherapeutics.com (VKTX)|Company Long-Term Debts SUPN|CPRX - Long-Term Debt|Company Long-Term Debt Denali Therapeutics Inc DNLI|Company Long-Term Loans and Borrowings HRMY|Biohaven Ltd. - Company Long-Term Debts|Long-Term Debt amylyx.com|TRVI (Trevi Therapeutics, Inc.) - Company Long-Term Liabilities|PRAX (Praxis Precision Medicines Inc) - Company Long-Term Debt|AVXL (Anavex Corp) - Company Long-Term Debts|Long-Term Debt CeriBell EEG CBLL|Company Long-Term Debt Prothena (PRTA)|Company Long-Term Debt ALEC (alector.com)|Annexon - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings OMER|NGNE: Company Long-Term Liabilities|AC Immune Inc - Amount of Long-Term Liabilities|VYGR: Company Long-Term Debts|neumoratx.com - Company Long-Term Loans and Borrowings|SCLX (Scilex) - Company Long-Term Debts|Long-Term Debt Tevogen Bio Holdings Inc. TVGN|Company Long-Term Debt Alpha Cognition (ACOG)|CGTX (cogrx.com) - Company Long-Term Loans and Borrowings|Company Long-Term Debts IKT (Inhibikase Therapeutics)|Company Long-Term Debts cassavasciences.com SAVA|ASRT - Company Long-Term Debt|Long-Term Liabilities COYA|VTGN: Company Long-Term Debts|Long-Term Debt Ovid Therapeutics (OVID)|Company Long-Term Liabilities ABOS|Company Long-Term Debts cervomed.com|Company Long-Term Liabilities ATHE (Alterity Therapeutics)|Amount of Long-Term Liabilities CLNN|Company Long-Term Debts PEPG (PepGen)|Long-Term Debt Volume jupiterneurosciences.com (JUNS)|Relmada Therapeutics - Company Long-Term Debts|annovisbio.com (ANVS) - Company Long-Term Liabilities|gracetx.com (GRCE) - Company Long-Term Debt|AIFF - Long-Term Debt Volume|KLTO (ANEW Medical) - Company Long-Term Debts|Company Long-Term Liabilities NeuroSense Therapeutics, Ltd. (NRSN)|Company Long-Term Debts RVPH|MTVA - Long-Term Debt|Company Long-Term Debt NeurAxis NRXS|Company Long-Term Loans and Borrowings HSDT|Passage Bio Corp - Company Long-Term Debts|Long-Term Debt Neuphoria Therapeutics Inc.|Minerva Neurosciences (NERV) - Company Long-Term Debt|Company Long-Term Indebtedness ATHA|ADXN (Addex Therapeutics Ltd) - Company Long-Term Debts|Long-Term Debt Alzamend ALZN|Company Long-Term Liabilities CYCN (Cyclerion Therapeutics)|Company Long-Term Debts protagenic.com (PTIX)|Company Long-Term Debt Pasithea Therapeutics Corp. KTTA|Company Long-Term Loans and Borrowings CRGT|ATXI - Company Long-Term Debt|Long-Term Debt Brainstorm Cell Therapeutics Inc.|CARA: Company Long-Term Debts|Company Long-Term Liabilities Chromocell|ELYM (Eliem Therapeutics, Inc.) - Company Long-Term Debts|Long-Term Debt Intra-Cellular ITCI|Company Long-Term Debt Longboard Pharmaceuticals, Inc. (LBPH)|MRNS (Marinus Pharmaceuticals Inc) - Company Long-Term Loans and Borrowings|Company Long-Term Debts NKGN (NKGen)|NeuroBo Pharma (NRBO) - Long-Term Debt|SAGE: Company Long-Term Liabilities|SNPX: Company Long-Term Debt|TRVN: Company Long-Term Debts|Long-Term Debt Vigil Neuroscience, Inc. (VIGL)|Company Long-Term Debt Anew Medical, Inc.